针对崩反应调解蛋白的自身抗体与脑病/骨髓病相关:单中心回顾性研究
Dongmei Wang1, Qiqi Wang1,2, Sanming Jie1
1Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
CNS neuroscience & therapeutics
|June 30, 2025
概括
崩反应介导蛋白 (CRMP) 自体抗体可能表明脑病变中免疫介导的神经元损伤. 这些抗体,特别是抗CRMP1抗体,在受影响患者中显示出作为神经元损伤生物标志物的诊断潜力.
科学领域:
- 神经免疫学 神经免疫学
- 自免疫神经学 自免疫神经学
- 生物标志物发现发现
背景情况:
- 崩反应调解蛋白 (CRMPs) 在神经系统中表达.
- 抗CRMP2和抗CRMP5抗体以前与自身免疫性脑炎 (AE) 有关.
- 这项研究调查了在怀疑免疫媒介脑病变/骨髓病变时CRMP自身抗体的诊断效用.
研究的目的:
- 评估CRMP自身抗体 (Abs) 的诊断价值在疑似免疫介导脑病变/骨髓病变的患者中.
- 为了确定CRMP自身抗体的患病率和临床关联.
- 探索CRMP自身抗体作为神经元损伤的潜在生物标志物.
主要方法:
- 对400名脑病变/骨髓病变患者和77名健康对照患者的回顾性分析.
- 使用基于细胞和基于组织的测定,测量血清和脑脊液 (CSF) 中对CRMPs的抗体.
- 临床数据收集,包括症状,CSF分析和治疗方案.
主要成果:
- 在400名患者中,22名 (5.5%) 的抗CRMP自身抗体检测呈阳性.
- 抗CRMP1是检测到的最常见的抗体 (77.3%的阳性病例).
- 患有抗CRMP自身抗体的患者表现出头痛频率增加和CSF化物水平更高;14人被诊断患有脑炎.
结论:
- 抗CRMP自身抗体可能意味着在脑病变中免疫媒介的神经元损伤.
- 这些抗体显示出作为神经元损伤的诊断生物标志物的潜力.
- 需要进一步的研究来阐明CRMP自身抗体在神经系统疾病中的作用.
更多相关视频
10:19High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
Published on: November 23, 2013
16.4K
07:20A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate NMDA Receptor in Blood
Published on: January 9, 2018
10.0K
相关概念视频
00:42Cross-reactivity
Overview
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...